Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7785929 | 0.90 | TDP1 (0.40) | TDP1POLBALDH1A1HPGDDAO | |
| SCHEMBL7785925 | 0.82 | PARP10 (0.44) | TDP1POLBALDH1A1HPGDMAPT | |
| SCHEMBL19873092 | 0.79 | TDP1 (0.48) | TDP1POLBALDH1A1HPGDNR4A1 | |
| SCHEMBL5520513 | 0.77 | TDP1 (0.47) | TDP1POLBALDH1A1HPGDMEN1 | |
| SCHEMBL10984187 | 0.77 | TDP1 (0.47) | TDP1POLBALDH1A1HPGDL3MBTL1 | |
| SCHEMBL11904537 | 0.77 | TDP1 (0.61) | TDP1POLBALDH1A1HPGDNR4A1 | |
| SCHEMBL38726 | 0.77 | TDP1 (0.61) | TDP1POLBALDH1A1HPGDNR4A1 | |
| SCHEMBL30466252 | 0.76 | POLB (0.45) | TDP1POLBALDH1A1HPGDNR4A1 | |
| SCHEMBL22823036 | 0.76 | TDP1 (0.45) | TDP1POLBALDH1A1HPGDMAPT | |
| SCHEMBL28289835 | 0.76 | TDP1 (0.45) | TDP1POLBALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1165531-C | Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing phenylenediamine groups | — | 2004-09-08 | — | — | CN | disclosed |
| EP-1137632-B1 | THIOUREA INHIBITORS OF HERPES VIRUSES | WYETH CORP (US) | 2004-07-28 | — | — | EP | disclosed |
| EP-1137645-B1 | ALPHA-METHYLBENZYL-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A PHENYLENEDIAMINE GROUP | WYETH CORP (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6555561-B2 | N-(5-((((5-Chloro-2,4-dimethoxyphenyl)amino)thioxomethyl)-amino)-2 -pyridinyl)-2-methylbenzamide, for example; inhibiting replication of a herpes virus | WYETH | 2003-04-29 | — | — | US | disclosed |
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2003-02-20 | — | — | US | disclosed |
| US-6462055-B2 | VIRICIDES | WYETH | 2002-10-08 | — | — | US | disclosed |
| EP-1144399-A3 | HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A SUBSTITUTED PHENYLENEDIAMINE GROUP | Wyeth (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1144397-A3 | HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING PHENYLENEDIAMINE GROUP | Wyeth (US) | 2002-09-11 | — | — | EP | disclosed |
| CN-1367785-A | Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing substituted phenylenediamine groups | AMERICAN HOME PROD (US) | 2002-09-04 | — | — | CN | disclosed |
| US-6426355-B1 | VIRICIDES; PREVENTION PRODUCTION | AMERICAN HOME PRODUCTS | 2002-07-30 | — | — | US | disclosed |
| WO-2000034269-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034260-A2 | ALPHA-METHYLBENZYL-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034268-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034261-A2 | HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A SUBSTITUTED PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034238-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034237-A2 | ACETAMIDE AND SUBSTITUTED ACETAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| US-5840917-A | ADMINISTERING TO MAMMAL TO ERADICATE HELICOBACTER PYLORI | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| WO-1998042347-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A PHOSPHORYLAMIDE AND AN AYNTIBIOTIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-01 | — | — | WO | disclosed |
| EP-0852498-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| WO-1997011705-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | HAVCR2, CCR6, CXCR6 | TDP1 452/4885POLB 1347/4885ALDH1A1 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.